AMAG Pharmaceuticals (NASDAQ:AMAG)‘s stock had its “hold” rating restated by Cantor Fitzgerald in a research note issued on Wednesday. They currently have a $17.00 target price on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 22.30% from the company’s previous close.
The analysts wrote, “Makena auto-injector is approved. AMAG announced today that the Makena auto-injector was approved. Although the PK data revealed a deficiency in the C max and AMAG disclosed that the FDA commented it would likely create a review issue, we suspect most investors believed the approval would occur.””
Other research analysts have also recently issued research reports about the company. BidaskClub raised AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday. Piper Jaffray Companies assumed coverage on AMAG Pharmaceuticals in a research report on Monday, October 23rd. They set a “neutral” rating and a $18.00 target price on the stock. ValuEngine cut AMAG Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 2nd. B. Riley reaffirmed a “hold” rating and set a $16.00 target price on shares of AMAG Pharmaceuticals in a research report on Monday, January 29th. Finally, Leerink Swann reaffirmed a “market perform” rating on shares of AMAG Pharmaceuticals in a research report on Friday, February 2nd. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating and two have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $19.44.
AMAG Pharmaceuticals (NASDAQ:AMAG) traded up $0.20 during midday trading on Wednesday, hitting $13.90. The stock had a trading volume of 1,025,248 shares, compared to its average volume of 1,001,212. The company has a market capitalization of $488.74, a P/E ratio of -2.29 and a beta of 0.79. AMAG Pharmaceuticals has a 52-week low of $11.93 and a 52-week high of $25.20. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.48 and a current ratio of 1.59.
Hedge funds have recently bought and sold shares of the business. Balter Liquid Alternatives LLC purchased a new position in AMAG Pharmaceuticals in the fourth quarter worth $120,000. Hartford Investment Management Co. purchased a new position in AMAG Pharmaceuticals in the third quarter worth $186,000. Cubist Systematic Strategies LLC purchased a new position in AMAG Pharmaceuticals in the third quarter worth $197,000. 361 Capital LLC purchased a new position in AMAG Pharmaceuticals in the third quarter worth $197,000. Finally, Aperio Group LLC purchased a new position in AMAG Pharmaceuticals in the third quarter worth $198,000.
COPYRIGHT VIOLATION NOTICE: “AMAG Pharmaceuticals (AMAG) Receives “Hold” Rating from Cantor Fitzgerald” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another publication, it was illegally copied and republished in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/15/amag-pharmaceuticals-amag-receives-hold-rating-from-cantor-fitzgerald.html.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.